Table 2.
Baseline descriptive and clinical characteristics of full sample treated with single infusion intravenous ketamine; subsample who subsequently completed the repeated infusions study; and IAT subsample who completed additional implicit and explicit measures of suicidality at baseline
| Single Infusion Sample (n=26)† | IAT Subsample (n=12) | Repeated Infusions Subsample (n=10) | |
|---|---|---|---|
| Age, mean (SD), y | 48.2 (11.8) | 50.1 (10.3) | 51.4 (14.6) |
| Female, No. (%) | 10 (39%) | 5 (42%) | 5 (50%) |
| Non-Hispanic Caucasian, No. (%) | 18 (69%) | 8 (67%) | 7 (70%) |
| IQ, mean (SD) | 115.0 (10.3) | 118.7 (10.2) | 115.7 (11.8) |
| Median household annual income | $15,000–24,999 | $10,000–14,999 | $15,000–24,999 |
| Time Since Illness Onset, mean (SD), y | 29.3 (13.3) | 29.7 (10.5) | 29.6 (13.0) |
| Age-of-Onset, mean (SD), y | 18.5 (12.2) | 20.4 (11.2) | 20.9 (15.4) |
| Number of Episodes, mean (SD) | 1.9 (1.7) | 2.3 (2.1) | 2.1 (1.7) |
| Duration of Current Episode >= 2y, No. (%) | 26 (100%) | 12 (100%) | 10 (100%) |
| Number of Failed Antidepressant Trials in Current Episode, mean (SD) | 6.0 (4.1) | 6.8 (3.9) | 7.1 (4.2) |
| History of Suicide Attempts, No. (%) | 5 (19%) | 3 (25%) | 1 (10%) |
| Clinically Significant Suicidal Ideation (MADRS-SI score >=4), No. (%) | 13 (50%) | 6 (50%) | 6 (60%) |
| MADRS-SI=4 | 10 (38.5%) | 5 (41.7%) | 5 (50%) |
| MADRS-SI=5 | 3 (11.5%) | 1 (8.3%) | 1 (10%) |
| MADRS-SI=6 | 0 | 0 | 0 |